PUTTINI, MIRIAM
 Distribuzione geografica
Continente #
NA - Nord America 1177
EU - Europa 418
AS - Asia 98
AF - Africa 2
Continente sconosciuto - Info sul continente non disponibili 2
OC - Oceania 1
Totale 1698
Nazione #
US - Stati Uniti d'America 1156
DE - Germania 107
CN - Cina 85
SE - Svezia 77
UA - Ucraina 72
IT - Italia 55
GB - Regno Unito 27
BE - Belgio 21
CA - Canada 21
DK - Danimarca 15
FI - Finlandia 12
IE - Irlanda 10
IN - India 6
RU - Federazione Russa 6
IR - Iran 3
NL - Olanda 3
RO - Romania 3
AT - Austria 2
EU - Europa 2
FR - Francia 2
TR - Turchia 2
CH - Svizzera 1
EG - Egitto 1
ES - Italia 1
HK - Hong Kong 1
LU - Lussemburgo 1
MY - Malesia 1
MZ - Mozambico 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PT - Portogallo 1
RS - Serbia 1
Totale 1698
Città #
Ann Arbor 370
Woodbridge 134
Chandler 96
Fairfield 92
Wilmington 85
Jacksonville 60
Houston 48
Frankfurt am Main 46
Dearborn 44
Ashburn 42
Seattle 33
Milan 31
Cambridge 23
Nanjing 23
Brussels 21
Princeton 20
Göttingen 18
Dublin 10
Lachine 10
Fremont 9
Guangzhou 9
Altamura 8
Lawrence 8
Nanchang 8
Shenyang 8
Beijing 6
Fürstenwalde 6
Tianjin 6
Edmonton 5
Kiev 5
Toronto 5
Gorgonzola 4
Jinan 4
Kunming 4
Philadelphia 4
Andover 3
Jiaxing 3
London 3
Boardman 2
Changsha 2
Falls Church 2
Hefei 2
Helsinki 2
Huizen 2
Langfang 2
Monmouth Junction 2
Mountain View 2
Nürnberg 2
Redmond 2
San Diego 2
Shanghai 2
Zanjan 2
Adliswil 1
Amsterdam 1
Auckland 1
Belgrade 1
Cairo 1
Central 1
Chicago 1
Duncan 1
Hangzhou 1
Kuala Lumpur 1
Leawood 1
Levico Terme 1
Lisbon 1
Luxembourg 1
Madrid 1
New York 1
Norwalk 1
Oslo 1
Otley 1
Ottawa 1
Perugia 1
Piemonte 1
Ripalta Cremasca 1
Robbio 1
Sacramento 1
San Francisco 1
San Mateo 1
Stockholm 1
Walnut 1
Wuhan 1
Zhangzhou 1
Totale 1373
Nome #
Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib 266
Imatinib Long-Term Effects Study: Global Independent Assessment of Imatinib in Chronic Myeloid Leukemia: Results At 8 Years 258
Imatinib long term effects study: three years of follow-up and assessment 227
Characterization of compound 584, an Abl kinase inhibitor with lasting effects 220
In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl(+) neoplastic cells 200
Oncogenic fusion tyrosine kinases as molecular targets for anti-cancer therapy 161
NPM/ALK binds and phosphorylates the RNA/DNA-binding protein PSF in anaplastic large-cell lymphoma 160
Inhibition of RET tyrosine kinase by SU5416 155
NPM/ALK co-localizes with, and phosphorylates PSF and other RNA-binding proteins 105
In vitro and in vivo activity of SKI-606, a novel Abl/Src inhibitor, against imatinib resistant BCR-ABL plus neoplastic 99
Totale 1851
Categoria #
all - tutte 2921
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2921


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019150 1111 311 168 35162730
2019/2020458 39313428 3951 7537 4935355
2020/2021446 13215649 47100 4049 471923
2021/2022149 512188 717 74 5181533
2022/2023313 32983730 1639 124 162180
Totale 1851